A case of hypophosphataemic osteomalacia secondary to deferasirox therapy

Research output: Contribution to journalArticleOther

13 Citations (Scopus)

Abstract

Patients with beta-thalassemia major require iron-chelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The availability of deferasirox (Exjade(R)), an orally active iron chelator, over the past 4 years represented a necessary alternative for patients requiring chelation therapy. However, there have been increasing reports of proximal renal tubular dysfunction and Fanconi Syndrome associated with deferasirox in the literature. We report a case of hypophosphataemic osteomalacia secondary to deferasirox therapy. (c) 2012 American Society for Bone and Mineral Research.
Original languageEnglish
Pages (from-to)219 - 222
Number of pages4
JournalJournal of Bone and Mineral Research
Volume27
Issue number1
DOIs
Publication statusPublished - 2012

Cite this

@article{f47a8b3180c44972b029159f08229b82,
title = "A case of hypophosphataemic osteomalacia secondary to deferasirox therapy",
abstract = "Patients with beta-thalassemia major require iron-chelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The availability of deferasirox (Exjade(R)), an orally active iron chelator, over the past 4 years represented a necessary alternative for patients requiring chelation therapy. However, there have been increasing reports of proximal renal tubular dysfunction and Fanconi Syndrome associated with deferasirox in the literature. We report a case of hypophosphataemic osteomalacia secondary to deferasirox therapy. (c) 2012 American Society for Bone and Mineral Research.",
author = "Francis Milat and Phillip Wong and Fuller, {Peter J} and Lilian Johnstone and Peter Kerr and James Doery and Strauss, {Boyd Josef Gimnicher} and Bowden, {Donald Keith}",
year = "2012",
doi = "10.1002/jbmr.522",
language = "English",
volume = "27",
pages = "219 -- 222",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - A case of hypophosphataemic osteomalacia secondary to deferasirox therapy

AU - Milat, Francis

AU - Wong, Phillip

AU - Fuller, Peter J

AU - Johnstone, Lilian

AU - Kerr, Peter

AU - Doery, James

AU - Strauss, Boyd Josef Gimnicher

AU - Bowden, Donald Keith

PY - 2012

Y1 - 2012

N2 - Patients with beta-thalassemia major require iron-chelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The availability of deferasirox (Exjade(R)), an orally active iron chelator, over the past 4 years represented a necessary alternative for patients requiring chelation therapy. However, there have been increasing reports of proximal renal tubular dysfunction and Fanconi Syndrome associated with deferasirox in the literature. We report a case of hypophosphataemic osteomalacia secondary to deferasirox therapy. (c) 2012 American Society for Bone and Mineral Research.

AB - Patients with beta-thalassemia major require iron-chelation therapy to avoid the complication of iron overload. Until recently, deferoxamine (DFO) was the major iron chelator used in patients requiring chronic hypertransfusion therapy, but DFO required continuous subcutaneous therapy. The availability of deferasirox (Exjade(R)), an orally active iron chelator, over the past 4 years represented a necessary alternative for patients requiring chelation therapy. However, there have been increasing reports of proximal renal tubular dysfunction and Fanconi Syndrome associated with deferasirox in the literature. We report a case of hypophosphataemic osteomalacia secondary to deferasirox therapy. (c) 2012 American Society for Bone and Mineral Research.

UR - http://onlinelibrary.wiley.com/doi/10.1002/jbmr.522/pdf

U2 - 10.1002/jbmr.522

DO - 10.1002/jbmr.522

M3 - Article

VL - 27

SP - 219

EP - 222

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -